MX363256B - Una composición de anticuerpo para la prevención o tratamiento de la infección por el virus mutante de la hepatitis b. - Google Patents

Una composición de anticuerpo para la prevención o tratamiento de la infección por el virus mutante de la hepatitis b.

Info

Publication number
MX363256B
MX363256B MX2015000349A MX2015000349A MX363256B MX 363256 B MX363256 B MX 363256B MX 2015000349 A MX2015000349 A MX 2015000349A MX 2015000349 A MX2015000349 A MX 2015000349A MX 363256 B MX363256 B MX 363256B
Authority
MX
Mexico
Prior art keywords
hepatitis
virus
antibody
present
mutant
Prior art date
Application number
MX2015000349A
Other languages
English (en)
Other versions
MX2015000349A (es
Inventor
Kim Se-Ho
Hong Kwang-Won
Hwan Chang Ki
Shin Wong-Won
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2015000349A publication Critical patent/MX2015000349A/es
Publication of MX363256B publication Critical patent/MX363256B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición de anticuerpo para su uso en la prevención o para tratar una infección con un virus de la hepatitis B (HBV) que tiene una mutación G145R del antígeno superficial del HBV (HBsAg) o una mutación YMDD (tirosina-metionina-aspartato-aspartato) de la ADN-polimerasa de la HBV, la composición está caracterizada porque comprende, como un ingrediente activo, un anticuerpo que incluye: una región variable de cadena pesada (VH) que tiene las secuencias de aminoácidos de SEQ ID NO: 2; y una región variable de cadena ligera (VL) que tiene la secuencia de aminoácidos de SEQ ID NO; 7.
MX2015000349A 2012-07-10 2013-07-08 Una composición de anticuerpo para la prevención o tratamiento de la infección por el virus mutante de la hepatitis b. MX363256B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120075063 2012-07-10
PCT/KR2013/006025 WO2014010890A1 (en) 2012-07-10 2013-07-08 An antibody composition for prevention or treatment of mutant hepatitis b virus infection

Publications (2)

Publication Number Publication Date
MX2015000349A MX2015000349A (es) 2015-09-29
MX363256B true MX363256B (es) 2019-03-19

Family

ID=49916280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000349A MX363256B (es) 2012-07-10 2013-07-08 Una composición de anticuerpo para la prevención o tratamiento de la infección por el virus mutante de la hepatitis b.

Country Status (14)

Country Link
US (2) US9683029B2 (es)
EP (1) EP2858674B1 (es)
JP (2) JP6113279B2 (es)
KR (2) KR101653261B1 (es)
CN (2) CN107375924A (es)
AU (1) AU2013287516B2 (es)
BR (1) BR112015000474A2 (es)
CA (1) CA2878155C (es)
EA (1) EA029321B1 (es)
ES (1) ES2712686T3 (es)
HR (1) HRP20190393T1 (es)
MX (1) MX363256B (es)
MY (1) MY178496A (es)
WO (1) WO2014010890A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6949012B2 (ja) * 2015-10-09 2021-10-13 シャアメン ユニバーシティ Ｂ型肝炎表面抗原に対する抗体及びその使用
CN108624564A (zh) * 2017-03-17 2018-10-09 艾博生物医药(杭州)有限公司 抗乙肝表面抗原的单抗隆抗体的制备和筛选
CN108624565A (zh) * 2017-03-17 2018-10-09 艾博生物医药(杭州)有限公司 一种抗乙肝表面抗原的单抗隆抗体制备和筛选
CN107132357B (zh) * 2017-03-23 2019-11-01 山东大学 一种逆转乙型肝炎病毒慢性感染的抗Tim-3抗体和α-galcer的组合及应用
CN107648602B (zh) * 2017-10-23 2020-09-01 苏州大学 二价乙肝疫苗及其制备方法
EP3801766A1 (en) * 2018-05-31 2021-04-14 Novartis AG Hepatitis b antibodies
FI3898668T3 (fi) 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
RS67553B1 (sr) 2018-12-20 2026-01-30 Humabs Biomed Sa Kombinovana hbv terapija
JP7629649B2 (ja) * 2019-09-11 2025-02-14 ザ ロックフェラー ユニバーシティー Ｂ型肝炎に対するヒト中和抗体に関連する組成物及び方法
KR20220117627A (ko) * 2021-02-17 2022-08-24 주식회사 녹십자 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
FR2815634B1 (fr) * 2000-10-20 2003-10-31 Biomerieux Sa Anticorps monoclonaux diriges contre des virus de l'hepatite b
KR100467706B1 (ko) * 2002-01-15 2005-01-24 주식회사 녹십자홀딩스 Ｂ형 간염 바이러스의 표면 항원에 대한 인간항체
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
CN100497604C (zh) 2002-02-07 2009-06-10 墨尔本保健公司 对核苷类似物具有改变的敏感性的病毒变体及其应用
WO2003087351A1 (en) * 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
CN1600856A (zh) * 2003-09-26 2005-03-30 陕西九州科技股份有限公司 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法
EP1871803B1 (en) 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체

Also Published As

Publication number Publication date
EP2858674B1 (en) 2019-01-30
AU2013287516B2 (en) 2016-07-07
JP2017095504A (ja) 2017-06-01
JP2015527317A (ja) 2015-09-17
CN104487090B (zh) 2017-06-16
CA2878155A1 (en) 2014-01-16
CA2878155C (en) 2019-01-08
US20150166637A1 (en) 2015-06-18
US9683029B2 (en) 2017-06-20
EA029321B1 (ru) 2018-03-30
HRP20190393T1 (hr) 2019-04-19
EA201500114A1 (ru) 2015-05-29
ES2712686T3 (es) 2019-05-14
AU2013287516A1 (en) 2015-01-29
EP2858674A4 (en) 2015-12-23
KR20160092042A (ko) 2016-08-03
EP2858674A1 (en) 2015-04-15
KR20150029699A (ko) 2015-03-18
KR101653261B1 (ko) 2016-09-12
JP6113279B2 (ja) 2017-04-12
BR112015000474A2 (pt) 2017-11-14
WO2014010890A1 (en) 2014-01-16
CN107375924A (zh) 2017-11-24
CN104487090A (zh) 2015-04-01
MY178496A (en) 2020-10-14
MX2015000349A (es) 2015-09-29
US20170260257A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
MY178496A (en) Antibody composition for prevention or treatment of mutant hepatitis b virus infection
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
PH12018550201A1 (en) Hepatitis b antiviral agents
EP4509180A3 (en) Humanized anti-claudin-1 antibodies and uses thereof
EA201391262A1 (ru) Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с
WO2007106404A3 (en) Vaccine for viruses that cause persistent or latent infections
WO2011015656A3 (en) Composition for treating hbv infection
MX373884B (es) Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
SG195383A1 (en) Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
SG10201806025TA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
EA201300135A1 (ru) Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний
EA201391685A1 (ru) Ингибиторы вируса гепатита с
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
MY163742A (en) Epitope and its use of hepatitis b virus surface antigen
NZ714347A (en) Method of treating intracellular infection
IN2014DN08266A (es)
EA201892212A1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
MX2021005588A (es) Composiciones inmunogenicas para el tratamiento de la hepatitis b.
MY184876A (en) Pharmaceutical composition for preventing cccdna formation of hepatitis b virus
TH169455A (th) องค์ประกอบแอนติบอดีสำหรับการป้องกัน หรือ การบำบัด ของการติดเชื้อ ไวรัสตับอักเสบ b ที่กลายพันธุ์
PH12021550987A1 (en) Anti-rabies monoclonal antibodies and cocktail thereof
WO2023287352A3 (en) Anti-hbv antibodies and uses thereof
MX337551B (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.
KIM HBV neutralizing human monoclonal antibody for liver transplantation & chronic hepatitis B treatment